Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters

類似資料

• Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer
  著者:: Brauch, Hiltrud, 等
  出版事項: (2008)
• Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen
  著者:: Schroth, Werner, 等
  出版事項: (2017)
• CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer – a reply
  著者:: Brauch, Hiltrud, 等
  出版事項: (2014)
• Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer
  著者:: Brauch, Hiltrud, 等
  出版事項: (2014)
• The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes
  著者:: Johänning, Janina, 等
  出版事項: (2017)